Updates for VA Clinicians in the Use of Bispecific Antibodies Across Later-Line Non-Hodgkin’s Lymphomas:
Summarizing Current Efficacy and Safety Data
Bi-specific antibodies for Non-hodgkin’s lymphoma treatment in Veterans Affairs patients: Current treatments, limitations and new promises
Post-Test/Evaluation

Exit Survey

Questions marked with a * are required

18%

Contact Information

First Name

Last Name

Email Address

Credentials/Degree (MD, DO, etc.)

Date of Participation

An 81-year-old woman with recurrent diffuse large B-cell lymphoma (DLBCL) following R-CHOP, polatuzumab vedotin/R, and CAR-T therapy has CD19low, CD20+ B cells and B-cell aplasia. What would you consider as the next step in treatment?

Odronextamab

Polatuzumab vedotin - Bendamustine/R

Tafasitamab/Lenalidomide

Loncastuximab tesirine

What is the next best treatment option for a 55-year-old woman with stage IIIA FL relapsed after treatments including BR, R-CHOP, ASCT, and lenalidomide + obinutuzumab?

CAR T-cell therapy

Mosunetuzumab

Tazemetostat

Loncastuximab tesirine